Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
SP Funds S&P 500 Sharia Industry Exclusions ETFTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.78 (market cap $29.60B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $59.12. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYSPUS
Market Cap
$29.60B
Sector
HealthBroad Market / Factor
52-Week High
$491.22$59.51
52-Week Low
$205.48$46.28
Enterprise Value
$27.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS trades at $59.11, up 0.27% today, with a bullish technical signal supported by moving averages. The stock shows strong momentum indicators but an overbought RSI-6. Dividend payments of $0.03 are scheduled for mid-2026, indicating income focus. Recent news highlights the resilience of US dividend strategies amid market concentration.

The outlook remains positive given technical strength and dividend consistency, but overbought conditions near-term suggest caution. Risks include market volatility and reliance on dividend strategy performance. Analyst sentiment is supportive, with institutional interest in dividend-focused equities.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About SP Funds S&P 500 Sharia Industry Exclusions ETF

SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.

Read more on SPUS